Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts.
Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts.
复制标题
DOI：
10.1158/1078-0432.ccr-09-0557
复制
发表时间：
2009-10-01
期刊：
影响因子：
--
通讯作者：
Yao Q
中科院分区：
文献类型：
--
作者：
Li M;Zhang Y;Bharadwaj U;Zhai QJ;Ahern CH;Fisher WE;Brunicardi FC;Logsdon CD;Chen C;Yao Q
Zinc levels have been correlated with cancer risk, though the role of zinc and zinc transporters in cancer progression is largely unknown. We have recently found that a zinc transporter, ZIP4, is overexpressed in pancreatic cancer. In this study, we have further deciphered the role that ZIP4 plays in a pancreatic cancer mouse model by silencing ZIP4. ZIP4 stable silencing was established in pancreatic cancer cell lines ASPC-1 (ASPC-shZIP4) and BxPC-3 (BxPC-shZIP4) by shRNA using retrovirus vectors. The stable cells were characterized in vitro and in vivo using a nude mouse xenograft model. Silencing of ZIP4 was associated with decreased cell proliferation, migration, and invasion. Both ASPC-shZIP4 and BxPC-shZIP4 cells showed a significant reduction in tumor volume and weight in the subcutaneous model, and decreased primary tumor weight in the orthotopic model compared with the vector control cells (ASPC-shV and BxPC-shV). Silencing of ZIP4 also caused reduced incidence of tumor metastasis in the mice and downsized the tumor grade. More importantly, silencing of ZIP4 significantly increased the survival rate of nude mice with orthotopic xenografts (P = 0.005). All ASPC-shZIP4-injected mice (100%) remained alive up to 32 days after tumor implantation, whereas only 30% of the ASPC-shV mice were alive at the same time point. CyclinD1 expression was decreased in the ASPC-shZIP4 xenografts. These results identify a previously uncharacterized role of ZIP4 in pancreatic cancer progression, and indicate that knocking down ZIP4 by shRNA might be a novel treatment strategy for pancreatic cancers with ZIP4 overexpression.
